Literature DB >> 32674846

Update on pediatric rhabdomyosarcoma: A report from the APSA Cancer Committee.

Daniel S Rhee1, David A Rodeberg2, Reto M Baertschiger3, Jennifer H Aldrink4, Timothy B Lautz5, Christa Grant6, Rebecka L Meyers7, Elisabeth T Tracy8, Emily R Christison-Lagay9, Richard D Glick10, Peter Mattei11, Roshni Dasgupta12.   

Abstract

BACKGROUND/
PURPOSE: Rhabdomyosarcoma is the most common soft tissue sarcoma in children and young adults and requires multimodality treatment. The purpose of this review is to present an update on risk stratification as well as surgical and medical management strategies in pediatric rhabdomyosarcoma.
METHODS: A comprehensive review of the current literature on pediatric rhabdomyosarcoma, including the most recent Children's Oncology Group studies and several international collaboratives, was performed by the authors and key findings were summarized in the manuscript.
RESULTS: FOXO1 fusion status is a stronger prognostic factor than histology and is now used for risk stratification in treatment protocols. For assessment of regional nodal involvement, FDG-PET-CT shows poor sensitivity and specificity to detect histologically confirmed nodal metastasis. Thus, surgical assessment of regional lymph nodes is required for rhabdomyosarcoma of the extremities or trunk as well as paratesticular rhabdomyosarcoma in patients ≥10 years of age, although adherence to surgical guidelines remains poor. Hemiscrotectomy performed for scrotal violation in paratesticular rhabdomyosarcoma has not shown an improvement in event free survival and is not recommended.
CONCLUSIONS: Surgical and medical treatment strategies for rhabdomyosarcoma in children continue to evolve. This review provides current evidence-based treatment standards with an emphasis on surgical care. TYPE OF STUDY: Review. LEVEL OF EVIDENCE: Level IV.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Pediatric cancer; Rhabdomyosarcoma; Soft tissue sarcoma; Surgery

Mesh:

Substances:

Year:  2020        PMID: 32674846     DOI: 10.1016/j.jpedsurg.2020.06.015

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  5 in total

1.  Advances in the treatment of pediatric solid tumors: A 50-year perspective.

Authors:  Michael P LaQuaglia; Justin T Gerstle
Journal:  J Surg Oncol       Date:  2022-10       Impact factor: 2.885

2.  Case Report: Pediatric Hepatic Rhabdomyosarcoma With Maximum Lifetime.

Authors:  Xu Li; Xiang Li; Dian-Fei Yang; Miao Li; Hong-Qin Xu; Shuang Zheng; Pu-Jun Gao
Journal:  Front Med (Lausanne)       Date:  2022-04-15

3.  Mitochondrial calcium uptake regulates tumour progression in embryonal rhabdomyosarcoma.

Authors:  Hsin Yao Chiu; Amos Hong Pheng Loh; Reshma Taneja
Journal:  Cell Death Dis       Date:  2022-04-30       Impact factor: 9.685

4.  Head and neck rhabdomyosarcoma with TFCP2 fusions and ALK overexpression: a clinicopathological and molecular analysis of 11 cases.

Authors:  Bin Xu; Albert J H Suurmeijer; Narasimhan P Agaram; Lei Zhang; Cristina R Antonescu
Journal:  Histopathology       Date:  2021-05-19       Impact factor: 7.778

Review 5.  Pediatric Rhabdomyosarcoma: Epidemiology and Genetic Susceptibility.

Authors:  Bailey A Martin-Giacalone; P Adam Weinstein; Sharon E Plon; Philip J Lupo
Journal:  J Clin Med       Date:  2021-05-09       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.